Safety and Feasibility of Transcatheter Aortic Valve Replacement in Patients With Hematologic Neoplasms

Read full text Summarise with VIRAT
Authors: Nicholas Prinz, Joshua Thomas, Mevin Mathew, Jeet J. Mehta, Bibhu D. Mohanty
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

For patients with severe, symptomatic aortic stenosis (AS) who are poor surgical candidates, transcatheter aortic valve replacement (TAVR) offers a less invasive alternative to surgical valve replacement. Patients with hematologic neoplasms and severe AS are a high-risk subset, with increased risk of bleeding and infection, who have historically been excluded from clinical investigation in TAVR. Prior case reports have demonstrated successful TAVR in patients with hematologic neoplasms; however, there remains minimal literature on TAVR in this population. We present a series of 10 patients with hematologic neoplasms who underwent successful TAVR. Our cohort experienced minimal periprocedural complications and demonstrated marked improvement in cardiovascular function, with few long-term cardiac complications and favorable survival at 1 year post-procedure. These findings suggest that TAVR may be a feasible therapy in patients with concomitant hematologic neoplasms and severe, symptomatic AS.

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Aortic Disease and Treatment Approaches Infective Endocarditis Diagnosis and Management

Publication details

Journal / source
JACC Case Reports
Volume
31
Issue
17
Pages
107552–107552
Publication date
26 March 2026
Language
EN